Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 8 | 2025 | 120 | 1.560 |
Why?
|
| Endocrine Surgical Procedures | 2 | 2023 | 5 | 1.450 |
Why?
|
| Health Expenditures | 2 | 2021 | 103 | 1.330 |
Why?
|
| Parathyroidectomy | 3 | 2023 | 49 | 1.300 |
Why?
|
| Surgeons | 3 | 2023 | 257 | 1.270 |
Why?
|
| Telemedicine | 5 | 2022 | 439 | 1.210 |
Why?
|
| Obesity, Morbid | 7 | 2025 | 185 | 1.170 |
Why?
|
| Ambulatory Care | 2 | 2020 | 390 | 1.040 |
Why?
|
| Fractures, Bone | 2 | 2019 | 187 | 1.030 |
Why?
|
| Thyroid Gland | 4 | 2023 | 104 | 0.990 |
Why?
|
| General Surgery | 4 | 2020 | 205 | 0.960 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2023 | 33 | 0.840 |
Why?
|
| Thyroidectomy | 3 | 2021 | 100 | 0.840 |
Why?
|
| Endocrine System Diseases | 2 | 2022 | 43 | 0.790 |
Why?
|
| Health Care Costs | 4 | 2024 | 372 | 0.720 |
Why?
|
| Relative Value Scales | 1 | 2021 | 12 | 0.720 |
Why?
|
| Precision Medicine | 2 | 2020 | 321 | 0.670 |
Why?
|
| Hypercalcemia | 1 | 2019 | 39 | 0.650 |
Why?
|
| Cost Savings | 1 | 2019 | 71 | 0.640 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 184 | 0.610 |
Why?
|
| Postoperative Care | 1 | 2020 | 301 | 0.600 |
Why?
|
| Critical Care | 2 | 2020 | 657 | 0.590 |
Why?
|
| Reoperation | 1 | 2021 | 829 | 0.570 |
Why?
|
| Pandemics | 4 | 2022 | 1112 | 0.570 |
Why?
|
| Quality of Health Care | 1 | 2020 | 391 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 290 | 0.540 |
Why?
|
| Program Evaluation | 1 | 2018 | 441 | 0.520 |
Why?
|
| Patient Safety | 1 | 2020 | 398 | 0.510 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 207 | 0.500 |
Why?
|
| Bone Density | 1 | 2017 | 319 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.470 |
Why?
|
| Leadership | 2 | 2020 | 230 | 0.470 |
Why?
|
| Referral and Consultation | 1 | 2018 | 542 | 0.460 |
Why?
|
| Laparoscopy | 3 | 2024 | 490 | 0.450 |
Why?
|
| Retrospective Studies | 19 | 2025 | 16344 | 0.440 |
Why?
|
| Gastrectomy | 2 | 2025 | 93 | 0.430 |
Why?
|
| Mass Screening | 1 | 2019 | 785 | 0.430 |
Why?
|
| Schools, Medical | 1 | 2014 | 110 | 0.420 |
Why?
|
| Education, Graduate | 1 | 2012 | 19 | 0.400 |
Why?
|
| Humans | 38 | 2025 | 125331 | 0.370 |
Why?
|
| United States | 10 | 2025 | 10922 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1654 | 0.350 |
Why?
|
| Sexism | 2 | 2020 | 38 | 0.320 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 408 | 0.320 |
Why?
|
| Physicians, Women | 2 | 2020 | 47 | 0.320 |
Why?
|
| Internship and Residency | 3 | 2020 | 1182 | 0.300 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3055 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 511 | 0.260 |
Why?
|
| Obesity | 7 | 2025 | 2249 | 0.250 |
Why?
|
| Male | 20 | 2025 | 61573 | 0.240 |
Why?
|
| Bupropion | 1 | 2025 | 29 | 0.240 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 35 | 0.240 |
Why?
|
| Naltrexone | 1 | 2025 | 70 | 0.230 |
Why?
|
| Female | 21 | 2025 | 66836 | 0.230 |
Why?
|
| Surgical Staplers | 1 | 2024 | 2 | 0.230 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2025 | 53 | 0.230 |
Why?
|
| Pain, Postoperative | 2 | 2024 | 259 | 0.220 |
Why?
|
| Hernia, Inguinal | 1 | 2024 | 42 | 0.220 |
Why?
|
| Gastroparesis | 1 | 2025 | 67 | 0.220 |
Why?
|
| Operative Time | 2 | 2023 | 165 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1270 | 0.220 |
Why?
|
| Middle Aged | 13 | 2025 | 26807 | 0.220 |
Why?
|
| Herniorrhaphy | 1 | 2024 | 81 | 0.220 |
Why?
|
| Prediabetic State | 1 | 2024 | 58 | 0.210 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 264 | 0.210 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 189 | 0.210 |
Why?
|
| Adult | 13 | 2025 | 29607 | 0.190 |
Why?
|
| Text Messaging | 1 | 2022 | 33 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2025 | 205 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 415 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2022 | 90 | 0.170 |
Why?
|
| Congresses as Topic | 1 | 2021 | 175 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2021 | 120 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 236 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 163 | 0.170 |
Why?
|
| Models, Economic | 1 | 2019 | 51 | 0.160 |
Why?
|
| Carcinoma, Papillary | 2 | 2017 | 71 | 0.160 |
Why?
|
| Authorship | 1 | 2019 | 29 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2019 | 53 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 83 | 0.160 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 70 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2019 | 47 | 0.160 |
Why?
|
| Social Media | 1 | 2021 | 106 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 94 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 608 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2020 | 308 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 126 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2024 | 4837 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 729 | 0.140 |
Why?
|
| California | 1 | 2017 | 129 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 19728 | 0.140 |
Why?
|
| Biopsy | 1 | 2021 | 1241 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2020 | 492 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2017 | 337 | 0.130 |
Why?
|
| Specialties, Surgical | 2 | 2014 | 79 | 0.120 |
Why?
|
| Hypertension | 1 | 2024 | 1330 | 0.120 |
Why?
|
| Faculty, Medical | 2 | 2020 | 262 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 474 | 0.120 |
Why?
|
| Educational Technology | 1 | 2014 | 7 | 0.120 |
Why?
|
| Teaching Materials | 1 | 2014 | 16 | 0.120 |
Why?
|
| Calcium | 1 | 2019 | 1101 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2024 | 1562 | 0.110 |
Why?
|
| Thyroid Nodule | 1 | 2013 | 19 | 0.100 |
Why?
|
| Lung | 1 | 2021 | 1487 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2017 | 939 | 0.100 |
Why?
|
| Economics | 1 | 2012 | 12 | 0.100 |
Why?
|
| Education, Public Health Professional | 1 | 2012 | 5 | 0.100 |
Why?
|
| Science | 1 | 2012 | 33 | 0.100 |
Why?
|
| Biomedical Technology | 2 | 2022 | 36 | 0.090 |
Why?
|
| Time Factors | 1 | 2021 | 6318 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 290 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2014 | 700 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 520 | 0.080 |
Why?
|
| Curriculum | 1 | 2014 | 726 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2014 | 1001 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 70 | 0.060 |
Why?
|
| Surgical Stapling | 1 | 2024 | 18 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2020 | 545 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12290 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2023 | 28 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 88 | 0.050 |
Why?
|
| Learning Curve | 1 | 2023 | 53 | 0.050 |
Why?
|
| Remission Induction | 1 | 2023 | 291 | 0.050 |
Why?
|
| Smartphone | 1 | 2022 | 38 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 221 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1332 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 186 | 0.040 |
Why?
|
| Technology | 1 | 2020 | 63 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 221 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 374 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 436 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 496 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 220 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 3134 | 0.030 |
Why?
|
| Family | 1 | 2020 | 567 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2081 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 9066 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 646 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1946 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2901 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 381 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 117 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 193 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 515 | 0.020 |
Why?
|
| Adolescent | 2 | 2024 | 19419 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 289 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3431 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5166 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6555 | 0.010 |
Why?
|
| Child | 1 | 2013 | 24575 | 0.010 |
Why?
|